pepinemab
pepinemab: developed by 1 company · 1 clinical trial tracked.
pepinemab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect pepinemab to VCNX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could pepinemab → VCNX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Huntington's disease
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| VACCINEX, INC. (VCNX) Huntington's disease | Phase 2 |
Clinical Trials (1)
Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer
Primary endpoint: Maximum Tolerated Dose (MTD) of expanded CD4 T cells
Interventionalopen28 targetStarted 2022-05Completion 2026-121 site · United StatesH. Lee Moffitt Cancer Center and Research Institute
Frequently asked questions
Who is developing pepinemab?
pepinemab is being developed by VACCINEX, INC..
How many clinical trials involve pepinemab?
BioSniper tracks 1 clinical trial involving pepinemab.